N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha...
-
Upload
anne-jenkins -
Category
Documents
-
view
219 -
download
2
Transcript of N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha...
NORTHWEST AIDS EDUCATION AND TRAINING CENTER
CROI 2015: Treatment and Cure Highlights
Shireesha Dhanireddy
Robert Harrington
March 17, 2014No financial conflicts of interest
Outline
• Treatment Studies- Tenofovir alafenamide (TAF) in a single-tablet regimen in initial
HIV-1 infection (Abstract # 113LB)
- Renal and bone TAF vs tenofovir disoproxil fumarate (TDF) (Abstract # 143LB)
• Cure - Immunoprophylaxis by gene transfer (Abstract #66)
Tenofovir Alafenamide
TAF vs TDF:
Sax P et al, CROI 2015, Abstract 143LB
Background
• TDF causes significant renal and bone toxicity
• TDF 300mg = TAF 25mg- But 90% lower circulating plasma TFV while maintaining high viral
activity
• Phase 2 study:- Comparable efficacy- TAF less renal and bone effects
Sax P et al, CROI 2015, Abstract 143LB
Study Design
Tx-Naïve AdultsHIV-1 RNA > 1000 c/mLeGFR > 50 mL/min
E/C/F/TAF qday
E/C/F/TDF qday (Stribild)
1:1
N=866
N=867
Week 0 48 96 144
Primary Endpoint
Sax P et al, CROI 2015, Abstract 143LBWohl D et al, CROI 2015, Abstract 113LB
• 2 phase 3 randomized, double-blind, double-dummy, active-controlled studies• GS104 (N. America, EU, Asia); GS 111 (N. America, EU, Latin America)
• Primary endpoint – proportion with HIV-1 RNA < 50 c/mL • Week 48 safety endpoints – serum creatinine, proteinuria, hip BMD, spine BMD
Baseline Characteristics
Sax P et al, CROI 2015, Abstract 143LB ; Wohl D et al, CROI 2015, Abstract 113LB
Median age, year 33 35
Sex, %
Male 85 85
Female 15 15
Race/ethnicity, %
Black or African 26 25
Hispanic 19 19
Median VL, log 4.58 4.58
% with VL >100K 23 23
Median CD4 count 404 406
% with CD4 count < 200 13 14
Median eGFR 117 114
% with Proteinuria (any grade) 10 10
E/C/F/TAF E/C/F/TDF
TAF vs TDF
Screened (n=2175)
TAF Arm(n=866)
TDF arm (n=867)
95% on treatment(n=821)
92% on treatment(n=796)
Sax P et al, CROI 2015, Abstract 143LB ; Wohl D et al, CROI 2015, Abstract 113LB
At 48 weeks
Week 48 Efficacy Data
Wohl D et al, CROI 2015, Abstract 113LB
TAF is non-inferior to TDF
Week 48 Efficacy Data
Wohl D et al, CROI 2015, Abstract 113LB
• Significantly greater increase in CD4 count in TAF arm
Week 48 : Laboratory Abnormalities
Any grade 3 or 4 lab abnormalities 20 20
Creatinine kinase elevation 7 6
LDL elevation (fasting) 5 2
Hypercholesterolemia (fasting) 2 1
Hematuria 2 2
AST elevation 2 2
Serum amylase elevation 2 3
Neutropenia (<1000) 2 2
ALT elevation 1 1
E/C/F/TAF E/C/F/TDF
% Adverse Events (all grades)No significant differences
Diarrhea 17 19
Nausea 15 17
Headache 14 13
URI 11 13
Nasopharyngitis 9 9
Fatigue 8 8
Cough 8 7
Vomiting 7 6
Arthralgia 7 5
Back pain 7 7
Insomnia 7 6
Rash 6 5
Pyrexia 5 5
Dizziness 5 4
E/C/F/TAF E/C/F/TDF
Week 48 Safety Data
• Drug Levels Findings- 91% reduction in TFV levels in plasma with TAF vs TDF
• Mean AUC 3410 (TDF) vs 297 (TAF)
- 4x higher intracellular levels of TFV with TAF vs TDF
Sax P et al, CROI 2015, Abstract 143LB
Week 48 Safety: Renal Endpoints
• No renal adverse events leading to discontinuation with TAF: - 0.5 (n=4) with TDF vs 0 with TAF
• Proteinuria decreased with TAF :
Week 48 Safety: Bone Results
• No fragility fractures seen in the study• Less effect on bone density by DEXA with TAF
Week 48 Safety: Lipid Results
• Lipids higher in TAF arm- TC:HDL ratio not statistically different
TAF Conclusions
• TAF non-inferior to TDF- 92% achieved virologic suppression- Low rates of virologic failure
• Favorable safety and tolerability- Discontinuation due to AEs low- Common AEs similar in both arms- TAF smaller decreases in eGFR- Significantly less proteinuria, albuminuria, and tubular proteinuria- Less impact on spine and hip bone mineral density
• Unanswered issues- Drug-drug interactions- Role in Hepatitis B/C co-infected patients
HIV Cure
Immunoprophylaxis By Gene Transfer:Shortcut To An HIV Vaccine
• Rarely, humans with chronic HIV infection will eventually produce antibodies that are potent and neutralize a broad range of HIV isolates
• Investigators asked if it was possible to use these already created antibodies to prevent HIV infection – bypassing a traditional vaccination approach
Johnson et al, CROI 2015, Abstract #66
Immunoprophylaxis By Gene Transfer:Shortcut To An HIV Vaccine
The Strategy
1. Identify those rare HIV+ individuals who make broadly neutralizing antibodies 2. Isolate the antibody gene from their plasma cells3. Clone it into a vector (AAV)
Inject into muscle Muscle cells make the broadly neutralizingantibody
Johnson et al, CROI 2015, Abstract #66
Immunoprophylaxis By Gene Transfer:Shortcut To An HIV Vaccine
First in mice
Muscle cells stain ++ for the antibody (b12IgG1)Muscle cells are antibody factories
Johnson et al, CROI 2015, Abstract #66
Immunoprophylaxis By Gene Transfer:Shortcut To An HIV Vaccine
Then in monkeys
1. Monkeys immunized2. Immunized and control animals challenged with SIV3. All un-immunized monkeys became viremic and died4. Immunized monkeys wereprotected
Antibody production continues for > 6 years
Johnson et al, CROI 2015, Abstract #66
Immunoprophylaxis By Gene Transfer:Shortcut To An HIV Vaccine
Johnson et al, CROI 2015, Abstract #66
• Protocol A0003: Phase 1 study of rAAV-PG9DP in healthy adults
• Future studies using 3rd and 4th generation broadly neutralizing anti-HIV Abs and other anti-infective molecules (e.g. IgG-CD4, Gardner, Nature, 2015; 519: 88-90)
Planned in people